干扰素联合利巴韦林及胸腺肽α1治疗对慢性丙型病毒性肝炎患者外周血T淋巴细胞亚群的影响

目的观察干扰素联合利巴韦林及胸腺肽α1治疗对慢性丙型病毒性肝炎(CHC)患者外周血T淋巴细胞亚群的影响。方法将46例CHC患者随机分为两组。治疗组26例,应用胸腺肽α11.6 mg/次,2次/周,皮下注射,持续6个月;同时肌肉注射干扰素300万U,隔日1次;口服利巴韦林0.4 g/次,2次/d。对照组20例,仅用干扰素联合利巴韦林治疗,用量、用法及疗程与治疗组相同。采用流式细胞术检测治疗前后两组患者外周血T淋巴细胞亚群变化。结果治疗6个月时,治疗组患者CD4+T淋巴细胞及CD4+/CD8+均较对照组显著升高(P<0.01),而CD8+T淋巴细胞较对照组显著下降(P<0.05)。结论干扰素联合利巴韦林及胸腺肽α1治疗CHC具有明显的协同作用,随着抗病毒、免疫调节的治疗,CD4+、CD8+T淋巴细胞免疫功能紊乱得到改善。

Influence of Interferon Combined with Ribavirin and Thymosin Alpha-1 on T Lymphocytes Subsets in Peripheral Blood in the Treatment of Chronic Hepatitis C

Objective To observe the influence of interferon combined with ribavirin and thymosin alpha-1 on T lymphocytes subsets in peripheral blood in the treatment of patients with chronic hepatitis C(CHC).Methods 46 patients with CHC were randomly divided into two groups.The treatment group(26 cases) was given thymosin alpha-1,with each time 1.6 mg and twice a week by subcutaneous injection for six months.Besides,the treatment group was also given interferon of 3 million units once every other day by muscle injection as well as ribavirin per os,with each time 0.4 g,twice a day.The control group was only given interferon combined with thymosin alpha-1 with the same dosage,usage and course of treatment as the treatment group.The changes of lymphocyte subsets T in peripheral blood among the patients were detected before and after the treatment by using flow cytometry.Results After six months treatment,the CD4+T cells and CD4+/CD8+in treatment group were significantly increased compared with those of the control group(P<0.01),while CD8+T cells were significantly decreased in the treatment group compared with those of the control group(P<0.05).Conclusion The combination of interferon,ribavirin and thymosin alpha-1 have obvious synergy in the treatment of CHC.Disorder of immune function of CD4+and CD8+T cells are improved through the therapy of antivirus and immune adjustment.